Telmisartan for Ovarian Cancer
Trial Summary
What is the purpose of this trial?
The primary study objective is to assess progression-free survival in patients with ovarian cancer receiving telmisartan plus selected standard of care chemotherapy regimens versus historical controls.
Do I have to stop taking my current medications for the trial?
The trial does not specify if you need to stop taking your current medications, but you cannot use ACE inhibitors like ramapril or have taken rituximab or amifostine within 30 days before starting telmisartan. It's best to discuss your current medications with the trial team.
How does the drug Telmisartan differ from other treatments for ovarian cancer?
Research Team
Ivy Wilkinson-Ryan, MD
Principal Investigator
Dartmouth Health
Eligibility Criteria
This trial is for women over 18 with high-grade serous ovarian cancer that's resistant to platinum-based chemotherapy. They must have a life expectancy of at least 2 months, be willing to use contraception, and have stable blood pressure. Excluded are pregnant or lactating women, those with significant heart conditions or infections, and anyone on certain medications like ACE inhibitors.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive oral telmisartan in combination with standard of care chemotherapy regimens
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Telmisartan
Find a Clinic Near You
Who Is Running the Clinical Trial?
Tyler J Curiel
Lead Sponsor
Dartmouth-Hitchcock Medical Center
Collaborator